High-profile COVID-19 vaccines developed in Russia and China share a potential shortcoming: They are based on a common cold virus that many people have been exposed to, potentially limiting their effectiveness, some experts say.
CanSino Biologics' vaccine, approved for military use in China, is a modified form of adenovirus type 5, or Ad5. The company is in talks to get emergency approval in several countries before completing large-scale trials, the Wall Street Journal reported last week.
A vaccine developed by Moscow's Gamaleya Institute, approved in Russia earlier this month despite limited testing, is based on Ad5 and a second less common adenovirus.
"The Ad5 concerns me just because a lot of people have immunity," said Anna Durbin, a vaccine researcher at Johns Hopkins University. "I'm not sure what their strategy is ... maybe it won't have 70% efficacy. It might have 40% efficacy, and that's better than nothing, until something else comes along."
Vaccines are seen as essential to ending the pandemic that has claimed over 845,000 lives worldwide. Gamaleya has said its two-virus approach will address Ad5 immunity issues.
Both developers have years of experience and approved Ebola vaccines based on Ad5. Neither CanSino nor Gamaleya responded to requests for comment.
Researchers have experimented with Ad5-based vaccines against a variety of infections for decades, but none are widely used. They employ harmless viruses as "vectors" to ferry genes from the target virus – in this case the novel coronavirus - into human cells, prompting an immune response to fight the actual virus.
But many people already have antibodies against Ad5, which could cause the immune system to attack the vector instead of responding to the coronavirus, making these vaccines less effective.
Several researchers have chosen alternative adenoviruses or delivery mechanisms. Oxford University and AstraZeneca based their COVID-19 vaccine on a chimpanzee adenovirus, avoiding the Ad5 issue. Johnson & Johnson's candidate uses Ad26, a comparatively rare strain.
Dr. Zhou Xing, from Canada's McMaster University, worked with CanSino on its first Ad5-based vaccine, for tuberculosis, in 2011. His team is developing an inhaled Ad5 COVID-19 vaccine, theorizing it could circumvent pre-existing immunity issues.
"The Oxford vaccine candidate has quite an advantage" over the injected CanSino vaccine, he said.
Xing also worries that high doses of the Ad5 vector in the CanSino vaccine could induce fever, fueling vaccine skepticism.
"I think they will get good immunity in people that don't have antibodies to the vaccine, but a lot of people do," said Dr. Hildegund Ertl, director of the Wistar Institute Vaccine Center in Philadelphia.
In China and the United States, about 40% of people have high levels of antibodies from prior Ad5 exposure. In Africa, it could be has high as 80%, experts said.
HIV RISK
Some scientists also worry an Ad5-based vaccine could increase chances of contracting HIV.
In a 2004 trial of a Merck & Co Ad5-based HIV vaccine, people with pre-existing immunity became more, not less, susceptible to the virus that causes AIDS.
Researchers, including top U.S. infectious diseases expert Dr. Anthony Fauci, in a 2015 paper, said the side effect was likely unique to HIV vaccines. But they cautioned that HIV incidence should be monitored during and after trials of all Ad5-based vaccines in at-risk populations.
"I would be worried about the use of those vaccines in any country or any population that was at risk of HIV, and I put our country as one of them," said Dr. Larry Corey, co-leader of the U.S. Coronavirus Vaccine Prevention Network, who was a lead researcher on the Merck trial.
Gamaleya's vaccine will be administered in two doses: The first based on Ad26, similar to J&J's candidate, and the second on Ad5.
Alexander Gintsburg, Gamaleya's director, has said the two-vector approach addresses the immunity issue. Ertl said it might work well enough in individuals who have been exposed to one of the two adenoviruses.
Many experts expressed skepticism about the Russian vaccine after the government declared its intention to give it to high-risk groups in October without data from large pivotal trials.
"Demonstrating safety and efficacy of a vaccine is very important," said Dr. Dan Barouch, a Harvard vaccine researcher who helped design J&J's COVID-19 vaccine. Often, he noted, large-scale trials "do not give the result that is expected or required."
Reuters
Tue Sep 01 2020
A logo of China's vaccine specialist CanSino Biologics Inc is pictured on the company's headquarters in Tianjin, following an outbreak of the coronavirus disease (COVID-19), China August 17, 2020 - REUTERS/Thomas Peter
Cisco akan kurangkan 7 peratus tenaga kerja globalnya
Langkah mengurangkan kakitangan itu dijangka melibatkan kos pra-cukai sehingga AS$1 bilion.
Jiwa SME: Kuih tradisonal sejuk beku 'diterbangkan' ke Tanah Suci
Inovasi pembuatan makanan sejuk beku, terutama kuih muih tradisional telah berjaya membawa produk itu ke peringkat global, terutama dalam memenuhi citarasa jemaah haji dan umrah rakyat Malaysia di Tanah Suci Mekah dan Madinah.
Gol sulung Mbappe bantu Real Madrid juarai Piala Super UEFA
"Ia adalah malam yang hebat. Ia adalah detik yang hebat untuk saya. Dan kami memenangi kejuaraan, yang penting - di Madrid anda perlu sentiasa menang."
“I love you Am, bahagialah di syurga firdausi” - Aufahanie
Air mata Aufahanie sudah kering meratapi pemergian abang tercinta, Nidza Afham yang ditemui meninggal dunia selepas dilaporkan hilang.
Konsert jelajah: Taylor Swift teruskan konsert London selepas ancaman keganasan
Taylor Swift akan meneruskan persembahan di London pada Khamis, meneruskan jelajah konsert terbesar dunia di tengah-tengah kebimbangan keselamatan susulan cubaan serangan Daesh memaksa pembatalan tarikh konsert di Vienna, minggu lalu.
Taliban rai ulang tahun ketiga pemerintahan Afghanistan
Kerajaan Taliban semalam meraikan ulang tahun ketiga pemerintahannya di Afghanistan dengan perarakan tentera yang memberi penghormatan kepada bom buatan sendiri yang digunakan ketika peperangan, pesawat pejuang dan perbarisan pasukan keselamatan.
Bapa bintang bola sepak Sepanyol, Lamine Yamal ditikam - Laporan
Mounir Nasraoui, bapa kepada Lamine Yamal, ditikam pada lewat Rabu di tempat letak kereta di bandar Mataro di timur laut Sepanyol.
Warga AS dihukum penjara 15 hari di Rusia kerana bersikap samseng
Mahkamah Moscow menjatuhkan hukuman penjara 15 hari kepada warga Amerika Syarikat Joseph Tater pada Rabu kerana bersikap samseng.
Putin anggap rundingan dengan Ukraine tidak berguna
Presiden Rusia Vladimir Putin menyifatkan, tindakan Ukraine yang menyerang orang awam memperlihatkan keengganan Kyiv menyelesaikan konflik peperangan dua negara dengan cara perdamaian.
Fadillah tiba di Peru, hadiri mesyuarat menteri-menteri tenaga APEC 2024
Timbalan Perdana Menteri, Datuk Seri Fadillah Yusof tiba Lima, Peru bagi menghadiri Mesyuarat Menteri-Menteri Tenaga (EMM) di bawah Kerjasama Ekonomi Asia Pasifik (APEC) yang berlangsung selama dua hari.
124 kes HIV baharu di Johor - Exco
Sebanyak 313 kes HIV dilaporkan di Johor sejak Januari hingga hari ini, kata Pengerusi Jawatankuasa Kesihatan dan Perpaduan Negeri, Ling Tian Soon.
Johor catat 494 kes HIV, 244 kes AIDS sehingga minggu epid 24/2022
Johor Bahru melaporkan kes HIV baharu tertinggi iaitu 122 kes.
Jangkitan baharu HIV menurun 70 peratus dalam tempoh 20 tahun - KKM
Rawatan ubat antiretroviral kepada orang yang hidup dengan HIV telah dipertingkatkan kepada 66 peratus pada tahun lepas.
Hapuskan ketidaksamaan untuk lenyapkan AIDS -Dr Adeeba
Stigma dan diskriminasi menjadi penghalang yang tidak diperlukan kepada perkhidmatan rawatan, pencegahan dan penjagaan HIV.
Berita antarabangsa pilihan sepanjang hari ini
Antara pelbagai berita luar negara yang disiarkan di Astro AWANI, berikut adalah antara yang paling menjadi tumpuan sepanjang hari ini.
Sebanyak 90 peratus penghidap HIV/AIDS adalah lelaki
Sebanyak 90 peratus penghidap HIV/AIDS di negara ini adalah terdiri daripada golongan lelaki, kata Ketua Sektor HIV/AIDS dan Hepatitis C Kementerian Kesihatan Dr Anita Suleiman.
MAF, Perkeso jalin kerjasama bantu pencarum HIV/AIDS
Pertubuhan Keselamatan Sosial (Perkeson) dan Yayasan Aids Malaysia (MAF) jalin kerjasama bagi memperkasakan ODHA dalam kalangan pencarum.
Pesakit AIDS juga manusia, dekati mereka. Agenda AWANI 9 malam ini
Akhiri ketidaksamaan layanan terhadap pesakit AIDS untuk kita bersama menangani penyakit tersebut.
Usaha tangani HIV/AIDS berdepan tekanan tatkala COVID-19 berlanjutan - Prof Adeeba
Antara cabaran lain termasuk kekuatan fizikal dan mental mereka yang menggerakkan inisiatif tersebut.
Agong bangga atas pelantikan Dr Adeeba sebagai anggota Majlis Sains WHO
Pakar penyakit berjangkit negara Prof Datuk Dr Adeeba Kamarulzaman atas pelantikan menjadi anggota Majlis Sains Pertubuhan Kesihatan Sedunia (WHO).